Eton Pharmaceuticals, Inc. financial data

Symbol
ETON on Nasdaq
Industry
Pharmaceutical Preparations
Location
21925 W. Field Parkway, Suite 235, Deer Park, IL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 172 % -40.6%
Quick Ratio 10.6 % +29.9%
Debt-to-equity 105 % +11.8%
Return On Equity -43.6 % -2333%
Return On Assets -21.3 % -2203%
Operating Margin -20 % -1099%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.8M shares +0.71%
Common Stock, Shares, Outstanding 25.7M shares +0.72%
Entity Public Float 84.7M USD +64.5%
Common Stock, Value, Issued 26K USD 0%
Weighted Average Number of Shares Outstanding, Basic 25.8M shares +0.72%
Weighted Average Number of Shares Outstanding, Diluted 25.7M shares +1.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 31.4M USD +8.14%
Research and Development Expense 5.28M USD +57.8%
General and Administrative Expense 19.7M USD +6.02%
Operating Income (Loss) -6.28M USD -1197%
Nonoperating Income (Expense) -110K USD -144%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -6.39M USD -2629%
Income Tax Expense (Benefit) 301K USD
Net Income (Loss) Attributable to Parent -6.69M USD -2758%
Earnings Per Share, Basic -0.27 USD/shares -100%
Earnings Per Share, Diluted -0.12 USD/shares -167%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.7M USD -18%
Accounts Receivable, after Allowance for Credit Loss, Current 4.87M USD +58%
Inventory, Net 2.07M USD +153%
Assets, Current 25.4M USD -3.41%
Property, Plant and Equipment, Net 45K USD -2.17%
Operating Lease, Right-of-Use Asset 210K USD +40.9%
Intangible Assets, Net (Excluding Goodwill) 6.12M USD +39.4%
Other Assets, Noncurrent 12K USD 0%
Assets 31.8M USD +2.88%
Accounts Payable, Current 2.13M USD -7.26%
Accrued Liabilities, Current 11.4M USD +98.8%
Liabilities, Current 18.2M USD +90%
Operating Lease, Liability, Noncurrent 145K USD +120%
Liabilities 18.4M USD +29.2%
Retained Earnings (Accumulated Deficit) -108M USD -6.61%
Stockholders' Equity Attributable to Parent 13.5M USD -19.5%
Liabilities and Equity 31.8M USD +2.88%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.47M USD -59.8%
Net Cash Provided by (Used in) Financing Activities -378K USD -671%
Net Cash Provided by (Used in) Investing Activities -1.88M USD
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 25.7M shares +0.72%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.73M USD -196%
Interest Paid, Excluding Capitalized Interest, Operating Activities 190K USD -12%
Deferred Tax Assets, Valuation Allowance 21.5M USD -0.54%
Deferred Tax Assets, Gross 21.5M USD -0.54%
Operating Lease, Liability 219K USD +51%
Depreciation 47K USD -6%
Payments to Acquire Property, Plant, and Equipment 14K USD
Lessee, Operating Lease, Liability, to be Paid 247K USD +57.3%
Property, Plant and Equipment, Gross 467K USD +10.9%
Operating Lease, Liability, Current 74K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 90K USD +291%
Lessee, Operating Lease, Liability, to be Paid, Year One 89K USD -1.11%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28K USD +133%
Lessee, Operating Lease, Liability, to be Paid, Year Three 23K USD
Deferred Tax Assets, Operating Loss Carryforwards 15.4M USD -10.1%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 10K USD -54.5%
Amortization of Intangible Assets 915K USD -53.7%
Depreciation, Depletion and Amortization 66K USD -57.4%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.09M USD -23%
Interest Expense 238K USD -10.2%